BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage develop…
Biotechnology
US, Palo Alto [HQ]
Cash Flow Statement
7 Sheets · From 2023 to 2017Configuration
In Million USD. Margins, Growth Rates In %
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Operating Cash Flow (OCF) | -40.00 | -136.00 | -253.00 | -399.00 | -497.00 | -419.00 | -527.00 | |
| Operating Cash (Net) | -40.00 | -136.00 | -253.00 | -399.00 | -497.00 | -419.00 | -527.00 | |
| Accounts Receivable | - - | - - | -2.00 | 2.00 | -19.00 | 15.00 | 15.00 | |
| Accounts Payable | 1.00 | 16.00 | -4.00 | - - | 2.00 | - - | 2.00 | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | - - | |
| Change | 1.00 | 22.00 | -10.00 | 14.00 | -4.00 | 28.00 | 5.00 | |
| Other WC | - - | 5.00 | -6.00 | 15.00 | -7.00 | 28.00 | 2.00 | |
| Investing Activities | ||||||||
| Used Cash (Net) | - - | -21.00 | -217.00 | -52.00 | -200.00 | 453.00 | 54.00 | |
| Capital Expenditure | - - | -18.00 | -5.00 | -7.00 | -48.00 | -6.00 | -1.00 | |
| Purchases of Investments | - - | - - | -212.00 | -287.00 | -643.00 | -193.00 | -137.00 | |
| Sale/Maturity of Investment | - - | - - | 5.00 | 242.00 | 477.00 | 532.00 | 193.00 | |
| Property, Plant, Equipment (P&PE) | - - | -18.00 | -5.00 | -7.00 | -48.00 | -6.00 | -1.00 | |
| Acquisitions (Net) | 2.00 | -2.00 | -5.00 | 21.00 | -35.00 | 120.00 | - - | |
| Other Investing Activities | - - | -2.00 | - - | -21.00 | 48.00 | 120.00 | - - | |
| Financing Activities | ||||||||
| Used Cash (Net) | -112.00 | -501.00 | -398.00 | -447.00 | -736.00 | -13.00 | -451.00 | |
| Debt Repayment | -4.00 | -1.00 | -175.00 | -536.00 | -124.00 | -20.00 | - - | |
| Dividends Paid | -1.00 | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | 190 | 76 | 208 | 6 | 466 | |
| Issued | 107.00 | 95.00 | 366.00 | 1.00 | 3.00 | 4.00 | 459.00 | |
| Repurchased | - - | - - | 175.00 | -75.00 | -204.00 | -1.00 | -6.00 | |
| Other Financing Activities | 114.00 | 407.00 | 33.00 | 1,595.00 | 1,065.00 | 4.00 | 458.00 | |
| Cash Balances | ||||||||
| Begin of Period | 20.00 | 92.00 | 436.00 | 364.00 | 358.00 | 396.00 | 416.00 | |
| End of Period | 92.00 | 436.00 | 364.00 | 358.00 | 396.00 | 416.00 | 394.00 | |
| Change | 72.00 | 343.00 | -72.00 | -5.00 | 37.00 | 20.00 | -22.00 | |
| Non-Cash Balances | ||||||||
| Depreciation and Amortization | - - | - - | - - | 3.00 | 5.00 | 6.00 | 6.00 | |
| Stock Based Compensation | 1.00 | - - | 21.00 | 58.00 | 99.00 | 91.00 | 108.00 | |
| Other | - - | 18.00 | 24.00 | 31.00 | 18.00 | -61.00 | 23.00 | |
| Highlighted metrics | ||||||||
| Free Cash Flow (FCF) | -40.00 | -154.00 | -258.00 | -407.00 | -546.00 | -425.00 | -529.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | -1,292.00 | -1,057.00 | -9,365.00 | 2,883.00 | 963.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
||||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - | - - | - - |